Compass Therapeutics Q2 net loss widens to $25.2 million; cash seen funding into 2028
Compass Therapeutics reported second-quarter 2026 results, with a net loss of $25.2 million, up from $19.9 million a year earlier, as research and development and general and administrative expenses rose. Cash and marketable securities fell to $180 million at June 30, 2026, which the company says should fund operations into 2028, and it expects FDA feedback on tovecimig in the third quarter.
Key points
- Q2 2026 net loss of $25.2 million, or $0.13 per share, versus $19.9 million, or $0.14 per share, in Q2 2025
- R&D expenses of $19.6 million, up 19%, and G&A expenses of $7.4 million, up 59%, from the year-earlier quarter
- Cash and marketable securities of $180 million at June 30, 2026, down from $209 million at December 31, 2025
- Company expects FDA feedback on tovecimig in Q3 2026 and an ESMO oral presentation in October 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.